Copyright
©The Author(s) 2016.
World J Cardiol. Jul 26, 2016; 8(7): 401-412
Published online Jul 26, 2016. doi: 10.4330/wjc.v8.i7.401
Published online Jul 26, 2016. doi: 10.4330/wjc.v8.i7.401
Table 2 Hemodynamic parameters at baseline and after milrinone loading
| Hemodynamic parameters | Patient 1 | Patient 2 | Reference values | ||
| Baseline | Post-milrinone loading | Baseline | Post-milrinone loading | ||
| RA (mmHg) | 15 | 15 | 5-7 | ||
| RV (mmHg) | 54/15 | Dec-58 | 15-30/1-5 | ||
| PA (mmHg) | 53/33 (40) | 56/21 (34) | 61/37 (45) | 15-30/4-10; mean < 20 | |
| PA O2 saturation | 49.50% | 57% | 60%-80% | ||
| PCWP (mmHg) | 29 | 15 | 30 | < 12 | |
| Cardiac output (L/min) | 5.1 | 7.1 | 3.3 | 6 | 4-8 |
| Cardiac index (L/min per meter squared) | 2.1 | 2.95 | 1.64 | 3.03 | 2.6-4.2 |
| PVR (WU) | 2.68 | 2.16 | 4.54 | < 3 WU | |
| Hemoglobin (g/dL) | 10.2 | 10.2 | 11.7 | 13.5-17.5 | |
- Citation: Jaiswal A, Nguyen VQ, Le Jemtel TH, Ferdinand KC. Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure. World J Cardiol 2016; 8(7): 401-412
- URL: https://www.wjgnet.com/1949-8462/full/v8/i7/401.htm
- DOI: https://dx.doi.org/10.4330/wjc.v8.i7.401